Baseline characteristics
A total of 154 participants were assessed for eligibility between November 2021 and February 2022. Among these, 44 patients were excluded because they did not meet the inclusion criteria (n=34), declined to participate (n=1), or for other reasons (n=9). Finally, 110 patients were enrolled and randomized into two groups that received either L-VA or H-VA dual therapy. Final follow-up was completed on the 31st of August 2022. One patient in each group was non-compliant, and three patients in the L-VA group and five patients in the H-VA group did not take a Flow chart of patient enrollment. ITT, intention to treat; PP, per protocol; L-VA, dual therapy consisting of low-dose amoxicillin (1000 mg b.i.d.) and vonoprazan (20 mg b.i.d.); H-VA, dual therapy consisting of high-dose amoxicillin (1000 mg t.i.d.) and vonoprazan (20 mg b.i.d.).Baseline characteristics of the participants.BMI, body mass index; L-VA, dual therapy consisting of low-dose amoxicillin (1000 mg b.i.d.) and vonoprazan (20 mg b.i.d.); H-VA, Dual therapy consisting of high-dose amoxicillin (1000 mg t.i.d.) and vonoprazan (20 mg b.i.d.).